RSV

From: Dr. Danielle Zerr, Medical Director of Infection Prevention and Seattle Children’s Pharmacy and Therapeutics Committee

Seattle Children’s began administering palivizumab (Synagis) on Nov 2 due to increasing RSV rates. We ask that community providers with patients who need Synagis provide it directly rather than referring patients to Seattle Children’s, due to capacity constraints at the hospital. Eligibility for palivizumab and nirsevimab follows the CDCs updated guidance.

A reminder about Nirsevimab:

• Nirsevimab is available at our hospital campus in limited supply for inpatients nearing discharge and outpatients with established subspecialty care at Seattle Children’s who do not have access through their PCP.
• Nirsevimab is not available at our Urgent Care sites.

For more information:

• CDC’s updated guidance (10-23-23) – addresses limited availability of product
• RSV Update | Washington Vaccine Association (10-12-23)
• AAP’s Nirsevimab FAQs
• Find family-facing resources about RSV at the end of the article “What Parents and Caregivers Should Know About RSV” (On the Pulse, 10-24-23)

Respiratory syncytial virus (RSV) rates at Seattle Children’s and statewide remain below threshold. We are not yet in RSV season. Nirsevimab (Beyfortus) continues to be available at Seattle Children’s hospital campus for inpatients nearing discharge and outpatients meeting criteria (those who do not have a PCP or who will age out of eligibility before their PCP has a supply). Nirsevimab is not available at our Urgent Care sites.

For more information:

• RSV Update | Washington Vaccine Association (10-12-23)
• CDC’s updated guidance (10-23-23) – addresses limited availability of product
• AAP’s Nirsevimab FAQs
• Find family-facing resources about RSV at the end of the article “What Parents and Caregivers Should Know About RSV” (On the Pulse, 10-24-23)

COVID-19 vaccines at Seattle Children’s

• Seattle Children’s is offering the 2023–2024 monovalent COVID-19 vaccine to patients at the hospital campus and Seattle Children’s Odessa Brown Children’s Clinic (OBCC).
  • Moderna’s monovalent COVID-19 vaccine will be offered to our patients staying in the hospital or coming for a clinic visit at the hospital campus.
  • Pfizer’s monovalent COVID-19 vaccine will be available to patients visiting OBCC.
• The COVID-19 vaccine is not available to patients at other locations.

For more information visit our COVID-19 page.